安徽医科大学学报
安徽醫科大學學報
안휘의과대학학보
Acta Universitatis Medicinalis Anhui
2015年
9期
1319-1322
,共4页
胸腺癌%病理%治疗%预后因素
胸腺癌%病理%治療%預後因素
흉선암%병리%치료%예후인소
thymic carcinoma%pathology%therapy%prognostic factor
目的 通过分析胸腺癌患者的临床病理特征及治疗情况,了解胸腺癌的预后相关因素. 方法 对进行手术切除的71例胸腺癌患者进行回顾性分析,按Masaoka分期标准进行分期,其中Ⅱ期7例,Ⅲ期33例,Ⅳ期31例. 并总结本组病例的病理分型、Masaoka分期、治疗及预后. 用Kaplan-Meier法计算生存率,用Logrank行差异显著性检验及生存因素分析. 结果 71 例患者的中位生存期为57. 2 个月,5年生存率为47. 9%,其中完整切除的25 例5 年生存率为68%,部分手术的46例5年生存率为36. 9%. 肿块直径大于或等于8的41例5年生存率为53. 6%,肿块最大径小于8的30例5年生存率为40%. Ⅱ、Ⅲ、Ⅳ期5年生存率分别为57. 1%、69. 7%、29. 0%. 不同病理学类型、鳞癌、腺癌、小细胞癌、腺鳞癌及类癌5 年生存率分别为55. 1%,14. 3%, 28. 6%,33. 3%,100%,手术方式、肿块最大径、Masaoka分期及不同病理学类型对生存差异有统计学意义(P<0. 05),术前治疗、术后放疗及分化程度对生存差异无统计学意义. 结论 手术方式、肿块大小、Masaoka分期及不同病理学类型是预后重要因素,手术方式和肿块大小是患者的独立预后影响因素. 术后辅助放疗可能不是预后不良的指标.
目的 通過分析胸腺癌患者的臨床病理特徵及治療情況,瞭解胸腺癌的預後相關因素. 方法 對進行手術切除的71例胸腺癌患者進行迴顧性分析,按Masaoka分期標準進行分期,其中Ⅱ期7例,Ⅲ期33例,Ⅳ期31例. 併總結本組病例的病理分型、Masaoka分期、治療及預後. 用Kaplan-Meier法計算生存率,用Logrank行差異顯著性檢驗及生存因素分析. 結果 71 例患者的中位生存期為57. 2 箇月,5年生存率為47. 9%,其中完整切除的25 例5 年生存率為68%,部分手術的46例5年生存率為36. 9%. 腫塊直徑大于或等于8的41例5年生存率為53. 6%,腫塊最大徑小于8的30例5年生存率為40%. Ⅱ、Ⅲ、Ⅳ期5年生存率分彆為57. 1%、69. 7%、29. 0%. 不同病理學類型、鱗癌、腺癌、小細胞癌、腺鱗癌及類癌5 年生存率分彆為55. 1%,14. 3%, 28. 6%,33. 3%,100%,手術方式、腫塊最大徑、Masaoka分期及不同病理學類型對生存差異有統計學意義(P<0. 05),術前治療、術後放療及分化程度對生存差異無統計學意義. 結論 手術方式、腫塊大小、Masaoka分期及不同病理學類型是預後重要因素,手術方式和腫塊大小是患者的獨立預後影響因素. 術後輔助放療可能不是預後不良的指標.
목적 통과분석흉선암환자적림상병리특정급치료정황,료해흉선암적예후상관인소. 방법 대진행수술절제적71례흉선암환자진행회고성분석,안Masaoka분기표준진행분기,기중Ⅱ기7례,Ⅲ기33례,Ⅳ기31례. 병총결본조병례적병리분형、Masaoka분기、치료급예후. 용Kaplan-Meier법계산생존솔,용Logrank행차이현저성검험급생존인소분석. 결과 71 례환자적중위생존기위57. 2 개월,5년생존솔위47. 9%,기중완정절제적25 례5 년생존솔위68%,부분수술적46례5년생존솔위36. 9%. 종괴직경대우혹등우8적41례5년생존솔위53. 6%,종괴최대경소우8적30례5년생존솔위40%. Ⅱ、Ⅲ、Ⅳ기5년생존솔분별위57. 1%、69. 7%、29. 0%. 불동병이학류형、린암、선암、소세포암、선린암급유암5 년생존솔분별위55. 1%,14. 3%, 28. 6%,33. 3%,100%,수술방식、종괴최대경、Masaoka분기급불동병이학류형대생존차이유통계학의의(P<0. 05),술전치료、술후방료급분화정도대생존차이무통계학의의. 결론 수술방식、종괴대소、Masaoka분기급불동병이학류형시예후중요인소,수술방식화종괴대소시환자적독립예후영향인소. 술후보조방료가능불시예후불량적지표.
Objective To explore the prognostic factor by analyzing clinical characters, pathologic features and treatment methods of thymic carcinoma. Methods From January 2000 to Deceber 2011, 71 patients received re-section of thymic carcinoma. They were analyzed retrospectively based on Masaoka stage(stageII 7,stageIII 33, stageIV 31). The clinical factors included histological classification, Masaoka stage, treatment and prognosis. Sur-vival rate was calculated and the survival curve was plotted by Kaplan-Meimer and Log-Rank method, Multi-analy-sis was carried out by COX regression. Results For these patients, the median survival time was 57. 2 months, the 5-year survival rate was 47. 9%. 25 patients received complete resection with 5-years survival rate 68%, 46 patients received partial resection with 5-years survival rate 36. 9%. 41 patients whose lump size was greater than or equal to 8 cm with 5-years survival rate 53. 6%, 40% with lower than 8 cm. Histology Masaoka staging with 5-years survival rate was stage II(57. 1%) , stage III(69. 7%) and stage IV(29. 0%) , respectively. Defferent his-tological type with 5-years survival rate squamous carcinoma(55. 1%) , adenocarcinoma (14. 3%) ,small cell car-cinoma ( 28. 6%) , adenosquamous carcinoma ( 33. 3%) , and carcinoid ( 100%) , respectively. The operation method, the maximum diameter, mass Masaoka stage and different pathology types for survival were statistically dif-ferent (P<0. 05). Preoperative treatment, postoperative radiotherapy and differentiation degree of survival had no statistical difference. Conclusion Surgical method, lump size, masaoka stage and histological type are the impor-tant factors affecting prognosis. Adjuvant radiotherapy maybe is not the poor prognosis factor of thymic tumors. Sur-gical method and lump size are the significant independent prognostic factors in patients with thymic tumors.
